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Abstract: 
Patients with Alzheimer’s disease (AD) are characterized by an altered sensitivity to cortisol-mediated modulation of circulating 
lymphocytes. Longitudinal studies are needed to address the clinical applicability of these abnormalities as prognostic factors. Therefore, we 
designed a longitudinal study to address the clinical applicability of physiologic modulation of Natural Killer (NK) cell activity as a 
prognostic factor in AD. NK activity was assessed as baseline measurement and in response to modulation by cortisol at 10
-6M.  To verify 
the immunophysiological integrity of the NK cell population, we tested augmentation of NK cytotoxicity by human recombinant interleukin 
(IL)-2 (100 IU/ml) as control. The response to modulation by cortisol or by IL-2 was significantly greater in patients with AD. Based on 
change in the Mini-Mental State score at entry and at 18 months, patients with AD could be assigned to a “fast progression” (Δ > 2 points) or 
to a “slow progression” group (Δ < 2 points).  The change in the response of NK cytotoxic activity to cortisol, and the strength of the 
association of this parameter with circulating activated T cells in time was greater in patients with Fast Progression vs. Slow Progression AD. 
These results suggest that changes in the response of NK cells to negative (e.g., cortisol) or positive modifiers (e.g., IL-2) follow progression 
of AD. 
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Background: 
Alzheimer's disease (AD) is a progressive disease of the brain 
caused by the deposit of β Amyloid protein. It is the most common 
type of dementia in the elderly. By 2010, over five million people 
will be diagnosed with AD in the US alone. The social and the 
medical costs of AD are mounting rapidly. Current interventions for 
AD include acetylcholinesterase inhibitors (e.g., Donezepil, 
[Aricept®]) that are indicated for patients with early symptoms of 
disease. [1, 2, 3] Recent data indicate a significant involvement of 
the T cell-mediated [4, 5], as well as the inflammatory arm [5, 6, 7] 
of the immune system, which appears to be correlated to the 
severity of AD. [5, 8] Both in vivo and in vitro studies have 
demonstrated individual differences, which can be attributed to 
variables specific to each individual patient. 
 
NK cells, defined immunophenotypically as devoid of the CD3/T 
cell receptor complex, but expressing the Fc receptor site, CD16, as 
well as the NK receptor CD56 (CD3-CD16+CD56+), are cytotoxic 
immune cells that do not require major histocompatibility complex 
(MHC) recognition. Dysregulations in NK responses are modulated 
by adaptive physiological processes, i.e., allostasis [5] that may be 
intrinsic to immune regulation (e.g., IL-2), or that may involve non-
immune factors, such as products of the neuroendocrine system. [9] 
 
Patients with AD exhibit baseline NK activity similar to age- and 
sex-matched control subjects.  However, the altered responsiveness 
to cortisol modulation of NK activity suggests that patients with AD 
may be characterized by a greater sensitivity to cortisol-mediated 
modulation of circulating lymphocytes. Hence, we propose the 
hypothesis that lack of sensitivity to cortisol modulation of NK 
activity could have clinically relevant applicability as a prognostic 
factor of AD. [8] 
 
Description: 
A longitudinal prospective cohort study was designed to address the 
clinical applicability of NK cell activity as prognostic factors in 
AD. 
 
NK cell activity of peripheral blood mononuclear (PBM) cells was 
measured in 18 patients (age range; 61-84 years old) with mild 
senile dementia of Alzheimer’s type (AD), and 10 normal healthy 
control subjects (four men, six women). Patients were selected on 
the basis of short history of disease and no medication at baseline. 
Following diagnosis, all patients were treated with the 
acetylcholinesterase inhibitor Donezepil (10 mg/daily).  Patients 
and subjects signed Informed Consent approved by the Institutional 
Review Board at our institution. 
 
All subjects were monitored at entry (T=0) and at six-month 
intervals. At each visit, patients underwent a battery of 
psychometric tests [Mini-Mental State Examination (MMSE); 
Mini-Mental State Examination-age and education corrected 
(MMSE-C); Functional Assessment Staging (FAST); index of 
Independence in Activities of Daily Living (ADL); Center for 
Epidemiology Studies–Depression (CES-D); Profile of Moods 
States (POMS)] to evaluate their cognitive performance and their 
psychological status. Based on change in the MMSE-C score at Bioinformation by Biomedical Informatics Publishing Group                                                    open access 
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entry and at 18 months follow-up, patients with AD were assigned 
to a “fast progression” (Δ > 2 points; n=8, two men, six women) or 
to a “slow progression” group (Δ < 2 points; (n=10; two men, eight 
women). 
 
NK activity of PBMC incubated with or without modifiers was 
expressed as Lytic Units (LU)/10
7 cells. [8-11] The summary data 
were expressed as means + standard deviation (SD), or standard 
error of the mean (SEM), as indicated in the text.  Parametric tests 
were used when the data verified the three assumptions of normal 
distribution, independence of measurements and homogeneity of 
variance. When these assumptions were violated, non-parametric 
tests were used. Statistical significance of differences in the values 
of cytotoxicity recorded under different conditions by the same 
PBM cells was determined by paired Student’s t -test (or 
Wilcoxon’s rank sign test). Differences between levels of 
cytotoxicity recorded under the same experimental condition in 
subjects and controls were statistically validated by unpaired two 
sample  t-test (or rank sum test). Repeated measure ANOVA (or 
Friedmann) was used to analyze the longitudinal data.  Statistical 
analysis was performed at a level of significance, α, of 0.10 due to 
the variability in NK activity customarily accounted for by 
individual differences, using Statistix (NH Analytical Software, 
USA) softwares and Analyze-It, version 1.72 (Analyze-It Software, 
Ltd.). 
 
Patients with AD were distinguished based on the pattern of 
progression of AD symptoms.  Patients with Fast Progression AD 
exhibit a significant drop in score of MMSE-C (Figure 1a).  Figure 
1b confirms these patterns with the ADL.   
 
The data in Table 1 show comparisons of the cortisol effect on 
modulating NK activity in the group of normal subjects, and in 
patients with AD assigned to a group of fast or slow progressing 
symptoms.  The data in the table indicate that as early as entry, a 
distinction can be made with respect to what group of patient is 
likely to progress faster in AD symptomatology, based on NK 
activity and on the response of NK cytotoxic activity to cortisol 
inhibitory and to IL-2 enhancing modulation.  
 
Baseline Cortisol  (10
-6M)  HrIL-2 (650 IU/ml)   
Mean 
(lytic units) 
+SEM Mean 
(lytic units) 
+SEM Mean 
(lytic units) 
+SEM 
Control  32.51 6.5  23.92 3.83  75.83 19.41 
Slow Progressing AD
1  23.26 3.31  15.89 2.38  79.39 28.50 
p vs. control  0.24   0.10   0.92  
Fast Progressing AD
1  21.13 3.40  15.33 2.60  38.46 6.82 
p vs. control  0.14   0.08   0.09  
Table 1:  Modulation of NK Activity (at entry) (1: as determined by drop in MMSE score at 18 months) 
 
The pattern of change of the modulatory response of NK activity in 
time is shown in Figure 1c and 1d as the median group percent 
change from baseline untreated cells to cells treated with the 
physiological modulator. Fig. 1c gives the change in NK 
modulation to cortisol among normal controls and patients with 
Slow Progression and Fast Progression AD at six-month intervals 
between entry and 18 month.  The trend of change for the control 
group can be expressed by the linear equation: y = -1.3971x - 22.64, 
R
2 = 0.2223.  The trend of change for the Slow Progression AD 
patient group can be given by the linear equation: y = -0.9193x - 
34.029, R
2 = 0.2296. The trend of change for the Fast Progression 
AD patient group is represented by the distinctly different linear 
equation: y = 0.302x - 31.41, R
2 = 0.2664. 
 
Fig. 1d shows the pattern of change in NK modulation by IL-2 
among normal controls and patients with Slow Progression and Fast 
Progression AD at six-month intervals between entry and 18 month.  
The trend of change for the control group can be expressed by the 
logarithmic equation: y = 24.777Ln(x) + 147.25, R
2 = 0.3606.  The 
trend of change for the Slow Progression AD patient group is 
represented by the logarithmic equation: y = -69.487Ln(x) + 
229.02, R
2 = 0.7786. The trend of change for the Fast Progression 
AD patient group is given by the essentially similar logarithmic 
equation: y = 81.205Ln(x) + 108.64, R
2 = 0.6307. 
 
In summary, spontaneous NK cell activity was not significantly 
different in AD subjects vs. normal control subjects at entry. The 
inhibitory effect of cortisol was significantly greater in patients with 
AD than in control subjects. NK activity was enhanced by IL-2 in 
all groups of subjects, albeit to a significantly lesser extent in 
patients with Fast Progression AD than in normal subjects, and 
compared to their cohorts with Slow Progression AD.  
 
Taken together, our results suggest that patients with AD maintain 
NK activity and numbers within normal range.  However, the 
cytotoxic activity of these cells is significantly more responsive to 
negative (cortisol) or positive physiologic modulators (IL-2) as the 
cognitive and behavioral symptoms associated with AD increase. 
These differences tend to accentuate with progression of the AD 
symptomatology.  
 
Taken together, our data indicate that NK activity and modulation 
of NK activity by cortisol will become a simple and reliable tool to 
monitor progression of the disease. These assays will become 
important biomarkers of the disease since they can reveal, as we 
show, their use and accessibility for risk assessment, early diagnosis 
and follow-up of patients with AD. Indeed, by performing the 
simple test of monitoring NK sensitivity to cortisol and to IL-2 
modulation in vitro at entry, reliable predictions of  the patients who 
would progress fast, vs. slowly to the more sever AD 
symptomatology is now possible. 
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Figure 1: (a) Pattern of progression of AD symptoms in terms of the score for the Mini-Mental State Examination-corrected for 
educational level and ethnicity at 0 to 18 months.  The data in the figure (mean + SD) show that the score on the MMSE-C dropped 
significantly faster in patients with Fast Progression AD (p<0.05), compared to their cohorts with Slow Progression AD.  (closed squares:  
control subjects; open squares:  patients with Slow Progression AD; closed circles: patients with Fast Progression AD); (b) Pattern of 
progression of AD symptoms in terms of the score for the Activities of Daily Living (ADL) (data presented as median values). (closed 
squares:  control subjects; open squares:  patients with Slow Progression AD; closed circles: patients with Fast Progression AD); (c) 
Pattern of change of the modulatory response of NK activity in time to cortisol among normal controls and patients with Slow 
Progression and Fast Progression AD at six month intervals between entry and 18 month; (d) Pattern of change in NK modulation by IL-
2 among normal controls and patients with Slow Progression and Fast Progression AD at six month intervals between entry and 18 
month. (data are presented as median group percent change from baseline untreated cells to cells treated with the physiological 
modulator). (closed squares:  control subjects; open squares:  patients with Slow Progression AD; closed circles: patients with Fast 
Progression AD) Bioinformation by Biomedical Informatics Publishing Group                                                    open access 
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